Multiple Sclerosis Medicine Gilenya Must Not Be Used In Pregnant Women

by Colleen Fleiss on  July 28, 2019 at 9:34 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

EMA's human medicines committee (CHMP) had recommended five medicines for approval.
Multiple Sclerosis Medicine Gilenya Must Not Be Used In Pregnant Women
Multiple Sclerosis Medicine Gilenya Must Not Be Used In Pregnant Women

The CHMP granted a positive opinion for Epidyolex* (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two forms of epilepsy. Epidyolex contains an active substance derived from cannabis and is the first to receive a positive opinion in the EU centralised procedure.

Show Full Article

The Committee recommended granting a conditional marketing authorisation for Vitrakvi* (larotrectinib), the first 'histology-independent' treatment in the European Union for solid tumours with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. NTRK gene fusions occur very frequently in a number of rare cancers.

Inbrija (levodopa) received a positive opinion for the treatment of symptoms of 'off' periods in Parkinson's disease.

The Committee adopted a positive opinion for Trogarzo (ibalizumab), for the treatment of HIV infection.

The CHMP recommended for approval the generic medicine Deferasirox Mylan (deferasirox), for the treatment of chronic iron overload due to blood transfusions in patients with beta thalassaemia major, non-transfusion-dependent thalassaemia syndromes and other anaemias.

Start of re-examination of recommendation for new medicine

The applicant for Evenity (romosozumab) has requested a re-examination of the Committee's negative opinion for this medicine adopted at the June 2019 meeting. The CHMP will re- examine the opinion and issue a final recommendation.

Eight recommendations on extensions of therapeutic indication

The Committee recommended extensions of indication for Empliciti, Keytruda, Lonsurf, Lucentis, Soliris, Stelara, Tecentriq and Zerbaxa.

Start of re-examination of recommendations on extension of therapeutic indications

The applicants for Revolade (eltrombopag) and Translarna (ataluren) have requested re-examination of the Committee's negative opinions for these medicines adopted at the June2019 meeting. The CHMP will re-examine the opinions and issue final recommendations.

Updated restrictions for Gilenya

The CHMP recommended that the multiple sclerosis medicine Gilenya (fingolimod) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using Gilenya, the medicine must be stopped and the pregnancy will have to be closely monitored.

Agenda and minutes

The agenda of the July 2019 meeting is published on EMA's website. Minutes of the June 2019 CHMP meeting will be published in the coming weeks.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

Drug Toxicity Breech Presentation and Delivery Chemotherapy Chemotherapy Drugs Pregnancy and Complications Infectious Mononucleosis Anemia in Pregnancy Iron & Folate Deficiency Anemia In Pregnancy Diet for Anemia in Pregnancy The Magic Feeling of Being A Mother 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive